214964-87-1

Upstream product

• 74702-93-5 2-(3-bromophenyl)propan-2-amine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1415502-44-1 methyl 3-{2-[(tert-butoxycarbonyl)amino]propan-2-yl}benzoate 

Relevant academic research and scientific papers

NOVEL NON-SYSTEMIC TGR5 AGONISTS

The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE

Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKKβ and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKKβ. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.

Pyrrolopyrimidines and Pyrrolopyridines

Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

4,1-benzoxazepines, their analogues, and their use as somatostatin agonists

The present invention provides a compound of the formula: wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; Z is an optionally substituted cyclic group or linear hydrocarbon group; R1is a hydrogen atom, an optionally substituted hydrocarbon group or heterocyclic ring; R2is an optionally substituted amino group; D is a bond or an optionally substituted divalent hydrocarbon group; E is a bond, —CON(Ra)—, —N(Ra)CO—, —N(Rb)CON(Rc)—, —N(Rd)COO—, —N(Re)SO2—, —COO—, —N(Rf)—, —O—, —S— —SO—, —SO2—, (in which Ra, Rb, Rc, Rd, Reand Rfare respectively a hydrogen atom or an optionally substituted hydrocarbon group); G is a bond or an optionally divalent substituted hydrocarbon group; L is a divalent group; ring B may form an optionally substituted non-aromatic condensed nitrogen-containing heterocyclic ring by combining with R2; X is two hydrogen atoms, an oxygen atom or a sulfur atom;is a single bond or a double bond, and Y is a nitrogen atom whenis a double bond, or an oxygen atom, —N(R4)— (in which R4is a hydrogen atom, an optionally substituted hydrocarbon group or an acyl group) or S(O)n(in which n is 0, 1 or 2) whenis a single bond, or a salt thereof, which have somatostatin receptor agonistic action.